- If you are wondering whether Danaher at around US$187 per share is starting to look appealing, or if the market still has it priced richly, this breakdown will help you frame that question clearly.
- The stock has recently been under pressure, with returns of a 2.3% decline over 7 days, 11.3% decline over 30 days, 18.8% decline year to date, and 10.5% decline over 1 year, which can change how investors think about both upside potential and risk.
- Recent coverage has focused on Danaher in the context of broader life sciences and diagnostics companies, with investors watching how funding, regulation, and long-term demand for testing and research tools could affect sentiment toward the group. This backdrop helps explain why the share price has been sensitive to sector-wide headlines, even when company-specific news has been limited.
- Right now Danaher scores 2 out of 6 on a structured valuation check. The next sections will unpack what that means across different methods, and then finish with a way of thinking about valuation that can give you a clearer picture of the stock.
Danaher scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.
Approach 1: Danaher Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today using a required return. It is essentially asking what all those future dollars are worth in current terms.
For Danaher, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $5.1b. Analyst inputs and extrapolated estimates point to free cash flow of $7.7b in 2029, with a series of projected cash flows between 2026 and 2035 that are discounted back to today using Simply Wall St's assumptions.
Bringing all those projected cash flows into today’s dollars leads to an estimated intrinsic value of about $224.64 per share. Compared with a share price around $187, the DCF output suggests the stock is roughly 16.7% undervalued on this set of assumptions.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Danaher is undervalued by 16.7%. Track this in your watchlist or portfolio, or discover 55 more high quality undervalued stocks.
Approach 2: Danaher Price vs Earnings
For a profitable company, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings, which is often how the market anchors valuation for established businesses.
What counts as a "normal" P/E depends a lot on how fast earnings are expected to grow and how risky those earnings are. Higher growth or perceived resilience can justify a higher P/E, while slower growth or higher uncertainty usually leads investors to pay a lower multiple.
Danaher currently trades on a P/E of 36.76x. That is above the Life Sciences industry average of 30.43x and also above the peer average of 29.64x, so on simple comparisons the stock is priced at a premium to its sector and similar companies.
Simply Wall St's Fair Ratio is a proprietary estimate of what a "reasonable" P/E might be given Danaher's earnings growth profile, industry, profit margins, market cap and risk characteristics. This tends to be more tailored than a plain peer or industry comparison because it looks at the company's own fundamentals rather than just where others are trading.
For Danaher, the Fair Ratio is 30.40x versus the current 36.76x P/E, which points to the shares looking expensive on this metric.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.
Upgrade Your Decision Making: Choose your Danaher Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Narratives let you attach your own story about Danaher to the numbers by linking your view on its future revenues, earnings and margins to a financial forecast, turning that into a Fair Value you can compare with the current price. This all happens within Simply Wall St's Community page, where Narratives update as new news or earnings arrive. One investor might see Danaher's fair value closer to the bullish US$310 target, while another leans toward the more cautious US$205. This gives you a clear, easy to use frame for deciding whether the stock looks expensive or cheap to you at any point in time.
Do you think there's more to the story for Danaher? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com